ISRCTN12125882CompletedNot Applicable
Influence of topical anti-VEGF (Ranibizumab) on the outcome of filtration surgery for glaucoma: A two phased study with a randomised placebo controlled trial
Horten Center, University of Zurich (Switzerland)0 sites50 target enrollmentStarted: August 18, 2010Last updated:
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 50
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Patients with primary open angle glaucoma (POAG), PEX and pigment dispersion Glaucoma
- •2. At least 18 years of age
- •3. No previous intraocular surgery undergoing trabeculectomy or phaco-trabeculectomy
Exclusion Criteria
- •1. Patients with primary angle closure glaucoma (PACG)
- •2. Glaucoma due to other causes
- •3. Previous intra- and extraocular surgery
- •4. Any surgery during the last 3 months
- •5. Patients with uveitis or inflammatory ocular surface disease
- •6. Patients with single eyes
- •7. Patients presenting the first postoperative day with bleb leak, hypotony or situations that potentially need another surgery
- •8. Pregnant and breast feeding women
- •9. Women planning to get pregnant
Investigators
Similar Trials
Completed
Not Applicable
The efficacy of topical NSAIDs for anti-VEGF therapy for vitreomacular diseaseretinal vein occlusion diabetic retinopathy age related macular degenerationJPRN-UMIN000014929TT East japan Tohoku Hospital200
Completed
Not Applicable
Anti-VEGF (bevacizumab/ranibizumab) versus RPE-choroid graft in the treatment of 1) non-responders to 3 intravitreal anti-VEGF injections, or 2) patients with AMD and pigment epithelium rip, or 3) patients with AMD and massive haemorrhage. A randomized trial.Exudative age-related macular degeneration in combination with either 1) visual loss of ¡Ý 15 letters on the ETDRS chart after 3 anti-VEGF injections, 2) subfoveal RPE-tear, or 3) massive submacular haemorrhage.NL-OMON29614Oogziekenhuis Rotterdam (OZR)240
Recruiting
Not Applicable
The effect of anti-VEGF treatments for neovascular,exudative and inflammatory ocular diseasesOcular diseases including neovascular, serous and inflammatory diseasesJPRN-UMIN000021589The department of ophthalmology,Tohoku university graduate School of Medicine3,000
Active, not recruiting
Phase 1
IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WITH ULCERATIVE COLITISulcerative colitisEUCTR2020-004391-18-FRCHU Amiens-Picardie100
Completed
Phase 3
Anti-VEGF (bevacizumab/ranibizumab) versus RPE-choroid graft in the treatment of 1) non-responders to 3 intravitreal anti-VEGF injections, or 2) patients with AMD and pigment epithelium rip, or 3) patients with AMD and massive haemorrhage. A randomized trial.age-relatede macular degeneration10047060NL-OMON33994Oogziekenhuis Rotterdam40